health-issue
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
https://ift.tt/bm12vBk Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old from …
Read more
health-issue
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
https://ift.tt/JUzW2YL Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progress…
Read more
health-issue
Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
https://ift.tt/4FVPzMi Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers fro…
Read more
health-issue
Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
https://ift.tt/SV7srXF from Sanofi - Aventis Groupe https://ift.tt/Sbfp6LR via IFTTT
Read more
health-issue
Media Update: ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies
https://ift.tt/BcI7X3j ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies from Sanofi - A…
Read more
health-issue
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
https://ift.tt/Ij3XSgP from Sanofi - Aventis Groupe https://ift.tt/rdPcjkR via IFTTT
Read more